NASH Drug Development Questions? US FDA Has Many Of The Answers
From biomarkers to treatment effect size, agency officials respond to some of more than a hundred questions that poured in during a webinar on development of drugs to treat the liver disease.
You may also be interested in...
The former Emory professor is now leading the US FDA Division of Hepatology & Nutrition after its inaugural director, Joseph Toerner, moves back to the infectious disease field as acting deputy in FDA’s vaccines office.
While plans to obtain accelerated approval of lanifibranor remain unchanged, Inventiva now plans to conduct the confirmatory Phase III in cirrhotic patients, meaning a shorter trial duration and possibly broader label.
Pharma companies are applying digital pathology throughout their research and development functions. Where are they now finding value?